BCM
ZYME icon

BlueCrest Capital Management’s Zymeworks ZYME Stock Holding History

BlueCrest Capital Management’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-30,987
Closed -$280K – 351
2023
Q1 		$280K Buy
+30,987
New +$270K 0.01% 228

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

BlueCrest Capital Management's ZYME Position: Q2 2023 in Review

BlueCrest Capital Management sold out of Zymeworks (ZYME) in Q2 2023, closing a stake of 30,987 shares — an estimated $280K sold.

BlueCrest Capital Management first reported a position in ZYME in Q1 2023 and held it in 1 quarter. The position peaked at $280K in Q1 2023. 137 funds tracked by Wall St. Rank hold ZYME as of Q2 2023.

  • BlueCrest Capital Management reported no remaining Zymeworks position as of Q2 2023 after selling out during the quarter.
  • BlueCrest Capital Management sold 30,987 Zymeworks shares in Q2 2023, an estimated $280K.
  • BlueCrest Capital Management first reported a position in Zymeworks in Q1 2023 and held it in 1 quarter.
  • BlueCrest Capital Management's Zymeworks position peaked at $280K in Q1 2023.
  • 137 funds tracked by Wall St. Rank held Zymeworks as of Q2 2023.

Based on BlueCrest Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.